The CRK Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, engineered to disrupt the endogenous CRK gene. This pooled population provides a heterogeneous loss-of-function model for investigating CRK-dependent signaling in a human Burkitt??s lymphoma background. The polyclonal format enables robust functional studies without single-cell clonal artifacts, making it suitable for broad screening and mechanistic dissection of CRK-mediated processes.
The Raji host cell line is a well-established model originating from a human Burkitt??s lymphoma, characterized by Epstein-Barr virus (EBV) positivity and a mature B lymphocyte phenotype. These cells are proficient in antigen presentation and antibody secretion, retaining key features of germinal center-derived B cells. The transformed yet differentiation-competent nature of Raji cells makes them a powerful system for studying B cell biology, lymphoma pathogenesis, and immune signaling networks.
CRK encodes an adaptor protein that serves as a central signaling node, coupling tyrosine-phosphorylated receptors and scaffolding proteins to downstream effectors. Upstream activation occurs through B cell receptor (BCR) stimulation, integrin ligation, SRC family kinases, ABL kinases, and receptor tyrosine kinases such as EGFR and PDGFR. CRK interacts with focal adhesion components p130Cas (BCAR1) and paxillin, and recruits guanine nucleotide exchange factors including C3G (RAPGEF1) and DOCK180 (DOCK1), thereby activating Rap1 and Rac GTPases. This triggers downstream cascades such as the ERK MAPK, JNK, and PI3K/AKT pathways, coordinating actin reorganization, integrin-mediated adhesion, and directed migration.
In Raji B cells, CRK-dependent signaling integrates microenvironmental cues from BCR and integrin ??4??1 engagement, which is critical for lymph node homing and retention. Disrupting CRK in this lymphoma context reveals how adaptor-mediated signal integration influences malignant B cell adhesion, trafficking, and survival. The polyclonal knockout pool enables researchers to assess overall pathway dependence while preserving the genetic diversity inherent to lymphoma models, offering insights into CRK??s role in B-cell lymphomas, chronic lymphocytic leukemia, and autoimmune disorders.
This product is ideally suited for a range of experimental applications including B cell adhesion and migration assays, phospho-signaling profiling (e.g., p-ERK, p-AKT), flow cytometric phenotypic analyses, and functional genomics screens. The knockout cells facilitate drug target validation and elucidation of crosstalk between BCR and integrin pathways. Researchers can employ Western blotting to confirm CRK ablation, transwell migration assays to assess chemokine-directed motility, and viability/apoptosis assays to study lymphoma cell dependencies. For additional technical information, please contact Ascent Research.
